在儿童中坚持复合人体生长激素治疗:影响因素和临床影响
Wenjing Chang1, Hua Jin2, Qin Zhou2
1Department of Child Health Care, The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University, Suzhou, China.
Frontiers in pediatrics
|September 18, 2025
概括
儿童对复合人体生长激素 (rhGH) 治疗的坚持总体上很高,特别是长效配方. 诸如年龄和生长缺陷严重程度等因素会影响坚持,更长时间的治疗可能会降低坚持.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 药物治疗 坚持药物治疗
- 增长激素治疗疗法 增长激素治疗
背景情况:
- 对于患有生长障碍的儿童,坚持复合人体生长激素 (rhGH) 治疗至关重要.
- 不坚持治疗对治疗疗效和患者的治疗结果构成重大挑战.
- 了解坚持模式和影响因素对于优化儿科生长障碍管理至关重要.
研究的目的:
- 评估儿科患者对rhGH治疗的坚持率.
- 为了确定影响RhGH治疗坚持性的关键因素.
- 探索改善儿童对rhGH治疗的坚持的策略.
主要方法:
- 在中国接受rhGH治疗的8621名儿科患者的回顾性分析.
- 依据所服用处方剂量的比例来评估坚持 (良好的坚持率≥86%).
- 后勤回归用于分析包括年龄,GH配方,治疗持续时间和地区在内的因素.
主要成果:
- 总体平均坚持率为92%.
- 长效GH配方的坚持性比每日注射 (91%) 高 (94%).
- 较年长的儿童,严重生长缺陷的儿童和特定地区的儿童表现出更好的坚持;较长的治疗持续时间与坚持下降相关.
结论:
- rhGH治疗的坚持是多因素的,受GH配方,患者年龄,生长缺陷严重程度,治疗持续时间和区域差异的影响.
- 长效的GH配方显著提高了坚持性.
- 量身定制的干预措施对于持续的坚持和最佳治疗结果至关重要.
相关概念视频
Nature and Nurture
22.2K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.2K
Hormones and Bone Tissue
3.7K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.7K
Role of Hematopoietic Growth Factors
3.1K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
3.1K
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
Insulin: Dosing Regimen and Adverse Effects
689
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
689


